stockportfolio.pro
Stocks / AMGN vs GILD
AMGN vs GILD
Amgen Inc. and Gilead Sciences, Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| Amgen Inc. (AMGN) | Gilead Sciences, Inc. (GILD) | |
|---|---|---|
| Market cap | $189.2B | $154.3B |
| Revenue (latest FY) | $36.75B | $29.44B |
| Net income (latest FY) | $7.71B | $8.51B |
| Revenue growth (5y CAGR) | 7.6% | 3.6% |
| Net margin | 21.0% | 28.9% |
| Return on equity | 89.1% | 37.5% |
| P/E ratio | 24.4 | 16.9 |
| Dividend yield | 2.8% | 2.6% |
| Profitable years (of last 10) | 10 | 10 |
| Positive free cash flow | Yes | Yes |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open AMGN — free Open GILD — freeFrequently asked questions
Which is bigger, AMGN or GILD?
Amgen Inc. is larger by market capitalization — $189.2B versus $154.3B.
Which grows faster, AMGN or GILD?
Over the last five fiscal years, Amgen Inc. grew revenue faster — 7.6%/yr versus 3.6%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.